Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crowdstrike Holdings Inc (CRWD) vs Zoetis Inc (ZTS) Price & Performance

Crowdstrike Holdings IncTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Crowdstrike Holdings Inc vs Zoetis Inc — how do they compare? Crowdstrike Holdings Inc trades at $274.86 (market cap $269.31B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Crowdstrike Holdings Inc is far larger — about 8.9× Zoetis Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Crowdstrike Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crowdstrike Holdings Inc for 97 Days and Zoetis Inc for 70 Days on average.

CRWDZTS
Market Cap
$269.31B$30.20B
Volume
9,381,5606,175,327
Sector
TechnologyHealth
52-Week High
$278.86$147.53
52-Week Low
$87.56$69.09
Typical Hold Time
97 Days70 Days
Enterprise Value
$265.11B$37.76B
Dividend Yield
—2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crowdstrike Holdings Inc

CrowdStrike (CRWD) trades at $275.04, up 3.62% today and near its all-time high, with a bullish technical signal from moving averages. The company shows strong revenue growth, reaching $3.95B in 2025, though net income remains negative at -$19.27M. Recent earnings beats and positive analyst sentiment (76% buy ratings) highlight momentum, while the stock trades at elevated valuation multiples like P/S of 49.86. Key developments include expansion into the OpenAI Marketplace and AI-driven cybersecurity demand.

Outlook: CrowdStrike's growth trajectory and AI positioning offer upside, but high valuations and profitability challenges pose risks. Analyst consensus target is $235.74, below current price, suggesting caution despite bullish sentiment. Competitive pressures and execution on net income conversion are critical for sustained gains.

Zoetis Inc

Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.

The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CRWD
84% Buy16% Sell
Avg holding period · 97 Days
ZTS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Crowdstrike Holdings Inc

CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.

Read more on CRWD →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →